The merger by incorporation process between Bristol Myers Squibb srl and Celgene srl and the related legal entities is concluded. From 1 August Bms will be the only local representative of the group and distributor of the company’s drugs in Italy.
“It is an exciting moment in the history of our company – says Emma Charles, General Manager Bristol Myers Squibb srl – With the acquisition of Celgene, the Bristol Myers Squibb pipeline is today among the largest and most diversified in the pharmaceutical world, with over 50 molecules in different stages of development. In particular, we operate in therapeutic areas where the need for new drugs or alternative therapies to existing ones is high – oncology, hematology, immunology, cardiovascular – and in Italy we can boast more than 40 molecules in development and over 140 active clinical trials, ”recalls Charles. “With the formal closure of the integration process in Italy, which lasted over 2 years – she adds – two important realities combine their talents to create an even stronger new bio-pharmaceutical company, focused on improving the lives of patients through science “.
BMS continues to invest in the future in innovation – underlines the company in a note – by collaborating with the scientific community, the academic world, institutions and patient associations, so that therapeutic innovation translates into better clinical outcomes for patients. “We have a history of scientific excellence focused on the research and development of cutting-edge therapies – highlights Charles – Pioneers in the discovery of immuno-oncology, we have revolutionized the way cancer is treated, improving long-term survival of patients and their quality of life. We have redefined the horizons of multiple myeloma treatment by changing the natural history of the disease with a broad portfolio of innovative drugs and we are now engaged in the field of cell therapies. For over 30 years we have brought innovation in cardiovascular diseases and continue to be pioneers in immunology, with new therapeutic approaches “.